FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Gertrude Peterson

Research Profile

Chemicals & Drugs

Disorders

Procedures

Antineoplastic Combined Chemotherapy Protocols

Physiology

Drug Resistance, Neoplasm

Concepts & Ideas

Co-author Network

Publications

TOP 3
Chad M Michener; Gertrude Peterson; Barbara Kulp; Kenneth D Webster; Maurie Markman
Carboplatin plus paclitaxel in the treatment of advanced or recurrent endometrial carcinoma.
Robert J Kim; Gertrude Peterson; Barbara Kulp; Kristine Zanotti; Maurie Markman
Skin toxicity associated with pegylated liposomal doxorubicin (40 mg/m2) in the treatment of gynecologic cancers.
Maurie Markman; Jon Markman; Kenneth Webster; Kristine Zanotti; Barbara Kulp; Gertrude Peterson; Jerome Belinson
Thrombocytopenia associated with second-line carboplatin-based chemotherapy for ovarian, fallopian tube, and primary peritoneal cavity cancers.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Gertrude Peterson (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2005: Chad M Michener; Gertrude Peterson; Barbara Kulp; Kenneth D Webster; Maurie Markman
Carboplatin plus paclitaxel in the treatment of advanced or recurrent endometrial carcinoma.
Journal of cancer research and clinical oncology 2005;131(9):581-4.
2005: Robert J Kim; Gertrude Peterson; Barbara Kulp; Kristine Zanotti; Maurie Markman
Skin toxicity associated with pegylated liposomal doxorubicin (40 mg/m2) in the treatment of gynecologic cancers.
Gynecologic oncology 2005;97(2):374-8.
2004: Maurie Markman; Jon Markman; Kenneth Webster; Kristine Zanotti; Barbara Kulp; Gertrude Peterson; Jerome Belinson
Thrombocytopenia associated with second-line carboplatin-based chemotherapy for ovarian, fallopian tube, and primary peritoneal cavity cancers.
Journal of cancer research and clinical oncology 2004;130(12):741-4.
2004: Maurie Markman; Kenneth Webster; Kristine Zanotti; Barbara Kulp; Gertrude Peterson; Jerome Belinson
Phase 2 trial of prolonged administration of oral topotecan in platinum/taxane-refractory ovarian, fallopian tube, and primary peritoneal cancers.
Gynecologic oncology 2004;95(1):109-13.
2004: Maurie Markman; Barbara Kulp; Gertrude Peterson
Grade 3 liposomal-doxorubicin-induced skin toxicity in a patient following complete resolution of moderately severe sunburn.
Gynecologic oncology 2004;94(2):578-80.
2004: Maurie Markman; Kenneth Webster; Kristine Zanotti; Gertrude Peterson; Barbara Kulp; Jerome Belinson
Phase 2 trial of carboplatin plus tamoxifen in platinum-resistant ovarian cancer and primary carcinoma of the peritoneum.
Gynecologic oncology 2004;94(2):404-8.
2004: Maurie Markman; Jonathan Markman; Kenneth Webster; Kristine Zanotti; Barbara Kulp; Gertrude Peterson; Jerome Belinson
Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(15):3120-5.
2004: Denise Uyar; Barbara Kulp; Gertrude Peterson; Kristine Zanotti; Maurie Markman; Jerome Belinson
Cardiac safety profile of prolonged (>or=6 cycles) pegylated liposomal doxorubicin administration in patients with gynecologic malignancies.
Gynecologic oncology 2004;94(1):147-51.
2004: Maurie Markman; Kenneth Webster; Kristine Zanotti; Gertrude Peterson; Barbara Kulp; Jerome Belinson
Examples of the marked variability in the relationship between the serum CA-125 antigen level and cancer-related symptoms in ovarian cancer.
Gynecologic oncology 2004;93(3):715-7.
2004: Maurie Markman; Kenneth Webster; Kristine Zanotti; Gertrude Peterson; Barbara Kulp; Jerome Belinson
Survival following the documentation of platinum and taxane resistance in ovarian cancer: a single institution experience involving multiple phase 2 clinical trials.
Gynecologic oncology 2004;93(3):699-701.
2004: Jonathan Markman; Kristine Zanotti; Kenneth Webster; Jerome Belinson; Gertrude Peterson; Barbara Kulp; Maurie Markman
Experience with the management of neutropenia in gynecologic cancer patients receiving carboplatin-based chemotherapy.
Gynecologic oncology 2004;92(2):592-5.
2004: Maurie Markman; Fred Hsieh; Kristine Zanotti; Kenneth Webster; Gertrude Peterson; Barbara Kulp; Ann Spicel; Jerome Belinson
Initial experience with a novel desensitization strategy for carboplatin-associated hypersensitivity reactions: carboplatin-hypersensitivity reactions.
Journal of cancer research and clinical oncology 2004;130(1):25-8.
2003: Maurie Markman; Kristine Zanotti; Gertrude Peterson; Barbara Kulp; Kenneth Webster; Jerome Belinson
Expanded experience with an intradermal skin test to predict for the presence or absence of carboplatin hypersensitivity.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(24):4611-4.
2003: Maurie Markman; Kristine Zanotti; Kenneth Webster; Gertrude Peterson; Barbara Kulp; Jerome Belinson
Phase 2 trial of single agent docetaxel in platinum and paclitaxel-refractory ovarian cancer, fallopian tube cancer, and primary carcinoma of the peritoneum.
Gynecologic oncology 2003;91(3):573-6.
2003: Maurie Markman; Paul Elson; Barbara Kulp; Gertrude Peterson; Kristine Zanotti; Kenneth Webster; Jerome Belinson
Carboplatin plus paclitaxel combination chemotherapy: impact of sequence of drug administration on treatment-induced neutropenia.
Gynecologic oncology 2003;91(1):118-22.
2003: Maurie Markman; Kenneth Webster; Kristine Zanotti; Barbara Kulp; Gertrude Peterson; Jerome Belinson
Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer.
Gynecologic oncology 2003;90(3):593-6.
2003: Maurie Markman; Kristine Zanotti; Barbara Kulp; Gertrude Peterson; Maurie Markman
Relationship between a history of systemic allergic reactions and risk of subsequent carboplatin hypersensitivity.
Gynecologic oncology 2003;89(3):514-6.
2001: Kristine Zanotti; Lisa A Rybicki; Alexander W Kennedy; Jerome Belinson; Kenneth D Webster; Barbara Kulp; Gertrude Peterson; Maurie Markman
Carboplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(12):3126-9.
2001: Maurie Markman; A Kennedy; Kenneth Webster; Gertrude Peterson; Barbara Kulp; Jerome Belinson
Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(7):1901-5.
2001: Maurie Markman; A Kennedy; Kenneth Webster; Barbara Kulp; Gertrude Peterson; Jerome Belinson
Neurotoxicity associated with a regimen of carboplatin (AUC 5-6) and paclitaxel (175 mg/m2 over 3 h) employed in the treatment of gynecologic malignancies.
Journal of cancer research and clinical oncology 2001;127(1):55-8.
2000: Maurie Markman; A Kennedy; Kenneth Webster; Barbara Kulp; Gertrude Peterson; Jerome Belinson
Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancer.
Gynecologic oncology 2000;79(1):116-9.
2000: Maurie Markman; A Kennedy; Kenneth Webster; Gertrude Peterson; Barbara Kulp; Jerome Belinson
Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum.
Gynecologic oncology 2000;78(3 Pt 1):369-72.
2000: Maurie Markman; A Kennedy; Kenneth Webster; Gertrude Peterson; Barbara Kulp; Jerome Belinson
The antiemetic efficacy of oral ondansetron plus intravenous dexamethasone in patients with gynecologic malignancies receiving carboplatin-based chemotherapy.
Gynecologic oncology 2000;78(1):43-6.
2000: Maurie Markman; A Kennedy; Kenneth Webster; Gertrude Peterson; Barbara Kulp; Jerome Belinson
Experience with prophylactic oral ciprofloxacin in gynecological cancer patients developing severe chemotherapy-induced neutropenia.
Journal of cancer research and clinical oncology 2000;126(5):298-300.
2000: Maurie Markman; A Kennedy; Kenneth Webster; Barbara Kulp; Gertrude Peterson; Jerome Belinson
Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland Clinic Cancer Center.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(1):102-5.
1999: Maurie Markman; A Kennedy; Kenneth Webster; Gertrude Peterson; Barbara Kulp; Jerome Belinson
An effective and more convenient drug regimen for prophylaxis against paclitaxel-associated hypersensitivity reactions.
Journal of cancer research and clinical oncology 1999;125(7):427-9.
1999: Maurie Markman; A Kennedy; Kenneth Webster; Barbara Kulp; Gertrude Peterson; Jerome Belinson
Use of low-dose oral prednisone to prevent paclitaxel-induced arthralgias and myalgias.
Gynecologic oncology 1999;72(1):100-1.
1998: Alexander W Kennedy; Maurie Markman; Kenneth D Webster; Barbara Kulp; Gertrude Peterson; Lisa A Rybicki; Jerome Belinson
Experience with platinum-paclitaxel chemotherapy in the initial management of papillary serous carcinoma of the peritoneum.
Gynecologic oncology 1998;71(2):288-90.
1998: Maurie Markman; A Kennedy; Kenneth Webster; Barbara Kulp; Gertrude Peterson; Jerome Belinson
Low-dose oral granisetron (1 mg) plus intravenous dexamethasone: efficacy in gynecologic cancer patients receiving carboplatin-based chemotherapy.
Gynecologic oncology 1998;71(1):113-5.
1998: Maurie Markman; A Kennedy; G Sutton; J Hurteau; Kenneth Webster; Gertrude Peterson; Barbara Kulp; Jerome Belinson
Phase 2 trial of single agent ifosfamide/mesna in patients with platinum/paclitaxel refractory ovarian cancer who have not previously been treated with an alkylating agent.
Gynecologic oncology 1998;70(2):272-4.
1998: Maurie Markman; Peter G Rose; E Jones; Ira R Horowitz; A Kennedy; Kenneth Webster; Jerome Belinson; Nancy Fusco; L Fluellen; Barbara Kulp; Gertrude Peterson; William P McGuire
Ninety-six-hour infusional paclitaxel as salvage therapy of ovarian cancer patients previously failing treatment with 3-hour or 24-hour paclitaxel infusion regimens.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(5):1849-51.
1998: Maurie Markman; A Kennedy; Kenneth Webster; Barbara Kulp; Gertrude Peterson; Jerome Belinson
Evidence that a "treatment-free interval of less than 6 months" does not equate with clinically defined platinum resistance in ovarian cancer or primary peritoneal carcinoma.
Journal of cancer research and clinical oncology 1998;124(6):326-8.
1997: Maurie Markman; A Kennedy; Kenneth Webster; Gertrude Peterson; Barbara Kulp; Jerome Belinson
Low-dose intravenous ondansetron (8 mg) plus dexamethasone: an effective regimen for the control of carboplatin-induced emesis.
Journal of cancer research and clinical oncology 1997;123(4):224-6.
1996: E Connelly; Maurie Markman; A Kennedy; Kenneth Webster; Barbara Kulp; Gertrude Peterson; Jerome Belinson
Paclitaxel delivered as a 3-hr infusion with cisplatin in patients with gynecologic cancers: unexpected incidence of neurotoxicity.
Gynecologic oncology 1996;62(2):166-8.
1996: M Markman; A Kennedy; Kenneth Webster; Barbara Kulp; Gertrude Peterson; Jerome Belinson
Continuous subcutaneous administration of mesna to prevent ifosfamide-induced hemorrhagic cystitis.
Seminars in oncology 1996;23(3 Suppl 6):97-8.
1996: Maurie Markman; A Kennedy; Kenneth Webster; Barbara Kulp; Gertrude Peterson; Jerome Belinson
Control of carboplatin-induced emesis with a fixed low dose of granisetron (0.5 mg) plus dexamethasone.
Gynecologic oncology 1996;60(3):435-7.
1995: Alexander W Kennedy; Gertrude Peterson; L Tuason; Jerome Belinson; Kenneth D Webster
Radical hysterectomy for cervical cancer: the effect of shorter length of stay on outcome.
Cleveland Clinic journal of medicine 1995;62(3):193-7.